A new study is attracting attention for suggesting that intratumoral T-cell activation can drive tumor elimination even without T-cell antigen specificity. The report’s central claim is that activating T cells locally inside tumors may be sufficient to trigger tumor control, potentially reframing assumptions underlying antigen-targeted and CAR-T–centric strategies. The underlying idea—whether broadly generalizable—matters because it could shift investment focus toward delivery and activation approaches that harness resident or recruited T cells rather than engineering highly specific receptors. If validated across tumor types and in controlled clinical settings, it could accelerate development of simpler activation modalities. For the field, the study’s “implications” highlight an area of active experimental tension: specificity versus activation potency and location. Developers will likely look for mechanistic confirmation and whether efficacy holds against heterogeneous tumor antigen landscapes. (Story coverage source: interpretive paper discussion.)